Breaking News
This is the future we shall bring into being
Elon Musk's Vision For The Future Looks Like A Movie
Phosphorus Munitions Fired by Israel Burn Groves, Orchards in Southern Lebanon
Iran's IRGC Warns It Will Expand 'Geography of the War' If the US Attacks Again
Top Tech News
BEYOND THE MOON: NASA plans a nuclear-powered fleet to push DEEPER into space
Big Oil Backs Mazama's $135 Million Bet On Superhot Geothermal
Quantum compass takes flight on Northrop's Lumberjack drone
Terrifying AI Behavior Even Its Creators Couldn't Explain
WW3 Near-Miss? AI Hallucinated Nuclear Weapons Components Aboard Chinese Vessel Bound For Iran
Stripe Is Building the Toll Road for the Machine Economy
Toyota Dakar hopeful swaps twin-turbo V6 for hydrogen fuel cells
4-min turbo-inflatable cubic camp castle is now available in the USA
Researchers Used Claude To Hack OpenAI Employee Accounts
Chinese Scientists Develop New Oil Refining Method That Cuts Energy Use by 90%
Oligodendrocyte progenitor cells repair damaged spine in humans in clinical trial...
AST's technology comes from one of the leading companies in regenerative medicine, BioTime, Inc., (NYSE: BTX) which spun off Asterias Biotherapeutics a few years ago and is also its largest shareholder. It is also worth pointing out that BioTime's CEO, Dr. Michael West, is one of the world's leading experts in regenerative and stem cell research
Asterias Biotherapeutics is a leading biotechnology company in the emerging field of regenerative medicine. The company's proprietary cell therapy programs are based on its immunotherapy and pluripotent stem cell platform technologies. Asterias is presently focused on advancing three clinical-stage programs which have the potential to address areas of very high unmet medical need in the fields of oncology and neurology.
Dr Michael West will use regenerative stem cell medicine to solve the primary diseases of aging.